Literature DB >> 11401640

Costs of medical and surgical treatment of glaucoma.

B M Calissendorff1.   

Abstract

PURPOSE: To compare county costs of medical and surgical glaucoma treatment.
METHODS: Medical records of 470 patients who underwent trabeculectomies in 1992 were scrutinized for a period of 3 years before and 3 years after surgery (including the year of surgery). Treatment costs were based on DRG prices, and drug consumption costs on the "defined daily dose" (DDD).
RESULTS: The costs rose steadily during the 3 years before surgery on account of more frequent visits and examinations and increased drug consumption. Mean total cost in the preoperative period was 13,355 SEK and that in the corresponding postoperative period, including surgery, was 23,684 SEK. The number of visits post-surgery was only slightly reduced, but there was a marked decrease in medication. However, the cost of the drugs was not correspondingly lower. Thirty percent of the patients later underwent cataract extraction.
CONCLUSION: From a strictly economic point of view glaucoma surgery is not profitable within a 3-year postoperative period.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401640     DOI: 10.1034/j.1600-0420.2001.790315.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  7 in total

Review 1.  The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Authors:  Jean-François Rouland; Gilles Berdeaux; Antoine Lafuma
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  The rising cost of glaucoma drugs in Ireland 1996-2003.

Authors:  F A Knox; M Barry; B McGowan; C O'Brien
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Medical outcomes of glaucoma therapy from a nationwide representative survey.

Authors:  Philippe Denis; Antoine Lafuma; Gilles Berdeaux
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Authors:  Stéphanie Payet; Philippe Denis; Gilles Berdeaux; Robert Launois
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

6.  Cost of glaucoma treatment in a developing country over a 5-year period.

Authors:  Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Study of minimally invasive radiofrequency ablation of the ciliary body for the treatment of glaucoma in rabbits.

Authors:  Baoke Hou; Fengxiang Wang; Zi Ye; Xin Jin; Yu Fu; Zhaohui Li
Journal:  Mol Med Rep       Date:  2019-12-31       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.